Company intelligence / Profile preview

January

New York, United Statesjanuary.ai ↗

Ownership: Private
Development stage: Other

Overview

Jan Biotech has developed a patented platform ("RNAamp") enabling direct, highly sensitive detection of viral RNA at the cellular level. Their work focuses on diagnostics to quantify latent HIV reservoirs and rapidly discriminate COVID mutations. They have received multiple NIH SBIR/STTR grants supporting these efforts. No therapeutic clinical results reported; focus is on diagnostic accuracy and sensitivity improvements.

Therapeutic areas: Infectious Diseases
Modalities: Molecular diagnosticsNucleic acid detection (RNA, DNA)
Industry: Molecular Diagnostics

Partnerships

none publicly disclosed; primary funding from NIH/SBIR/STTR grants

Beyond the preview

Go deeper on January.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on January.

Explore the full profile